PRAY.JK Famon Awal Bros Sedaya
- Market cap
- IDR 9.84T
- P/E
- 53.6x
- P/B
- 3.01x
- ROE
- 3.6%
- Dividend yield
- -
- Fundamental score
- 1.3/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is PRAY.JK undervalued?
Graham numberPRAY.JK trades 167.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Famon Awal Bros Sedaya fundamental analysis
5 of 22 checks passedROE 0/2
Low return on equity (3.6%), below 10%.
ROA 0/1
Return on assets (1.9%) is below the industry median (2.3%).
Profit Consistency 2/2
Profitable for 7 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (5.0%) is above the 5-year average (-5.6% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (5.0%) is below the industry median (20.0%).
Revenue Growth 2/2
Revenue grew 17.0% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (60.4%), up to 100%.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 0/1
EBIT is 2.8x against interest expense, below 5x.
PE vs Market 0/1
PE (52.8x) is above the market median (12.0x).
PE vs Industry 0/1
PE (52.8x) is above the industry median (19.9x).
PBV 0/1
Price to book (3.0x) is above the industry median (1.2x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 156.8, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Famon Awal Bros Sedaya stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Famon Awal Bros Sedaya
PT Famon Awal Bros Sedaya Tbk operates a network of hospitals in Indonesia. The company offers mother and child center, heart and vascular center, trauma center, cancer center, urology center, brain and neurocenter, eye center, and sports clinic, and orthopedic center. It also provides other health services such as clinical laboratories, homecare, and medical evacuation, as well as other healthcare services. PT Famon Awal Bros Sedaya Tbk was founded in 1997 and is based in K…
Full company profileFamon Awal Bros Sedaya financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Famon Awal Bros Sedaya annual financial statements (IDR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 1.01T | 1.34T | 1.83T | 1.52T | 1.84T | 2.10T | 2.44T | 2.87T |
| Gross Profit | 325B | 559B | 786B | 384B | 519B | 599B | 676B | 702B |
| Operating Income | 169B | 374B | 515B | 63.4B | 204B | 261B | 258B | 231B |
| EBITDA | 252B | 482B | 644B | 251B | 443B | 555B | 529B | 677B |
| Net Income | 122B | 282B | 326B | 62.5B | 217B | 201B | 211B | 117B |
| EPS | 8.75 | 20 | 23 | 4.48 | 16 | 14 | 15 | 8.40 |
| Balance Sheet | ||||||||
| Total Assets | 1.91T | 2.41T | 3.12T | 3.96T | 4.70T | 5.07T | 6.15T | 6.31T |
| Total Liabilities | 728B | 928B | 1.27T | 1.25T | 1.77T | 1.94T | 2.68T | 2.79T |
| Shareholders' Equity | 1.10T | 1.39T | 1.73T | 2.59T | 2.80T | 3.01T | 3.23T | 3.29T |
| Cash & Short-term Investments | 210B | 312B | 578B | 1.10T | 1.10T | 947B | 736B | 568B |
| Total Debt | 479B | 581B | 890B | 896B | 1.28T | 1.43T | 1.93T | 1.99T |
| Cash Flow | ||||||||
| Operating Cash Flow | 118B | 304B | 480B | 173B | 266B | 309B | 461B | -81.9B |
| Capital Expenditure | 173B | 288B | 463B | 444B | 538B | 616B | 864B | 362B |
| Free Cash Flow | -55.8B | 16.7B | 16.9B | -271B | -272B | -307B | -403B | -444B |
| Ratios | ||||||||
| ROE | 11.1% | 20.3% | 18.8% | 2.4% | 7.8% | 6.7% | 6.5% | 3.6% |
| ROA | 6.4% | 11.7% | 10.4% | 1.6% | 4.6% | 4.0% | 3.4% | 1.9% |
| Net Profit Margin | 12.0% | 21.1% | 17.9% | 4.1% | 11.8% | 9.6% | 8.7% | 4.1% |
| Debt to Equity | 0.43x | 0.42x | 0.51x | 0.35x | 0.46x | 0.48x | 0.60x | 0.60x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Famon Awal Bros Sedaya dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | IDR 100B | 7.19 | 160.6% |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Famon Awal Bros Sedaya
- Insiders 94.56%
- Institutions 4.72%
- Public & others 0.72%
- Shares outstanding 14.0B
- Free float 1.14B
Famon Awal Bros Sedaya company profile
- Company name
- Famon Awal Bros Sedaya
- Ticker
- PRAY.JK
- Exchange
- Jakarta Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 7,352
- Fiscal year end
- December
- Address
- Graha Cempaka Mas Blok D/5-6, Kemayoran, Indonesia, 10640
- Phone
- 62 21 4290 0203
- Website
- primayahospital.com
About Famon Awal Bros Sedaya
PT Famon Awal Bros Sedaya Tbk operates a network of hospitals in Indonesia. The company offers mother and child center, heart and vascular center, trauma center, cancer center, urology center, brain and neurocenter, eye center, and sports clinic, and orthopedic center. It also provides other health services such as clinical laboratories, homecare, and medical evacuation, as well as other healthcare services. PT Famon Awal Bros Sedaya Tbk was founded in 1997 and is based in Kemayoran, Indonesia.
Famon Awal Bros Sedaya management
4- Engineer Arfan AwaloeddinPresident Director
- Yoshen Danun M.B.A.Finance Director & Director
- Nada PradiptaHead of Internal Audit · born 1987
- Mesri SabrianaCorporate Secretary